Evidence map›Paper›PMID 41023053›Full record

ArticleScientific reports2025

Identification of a free-N-glycan with difucosylated type-1 lactosamine in cancerous tissue and its validation for cancer diagnosis by urinary testing.

Miki Tanaka-Okamoto, Ken Hanzawa, Takashi Yamamoto, Kazuyoshi Ohkawa, Ken-Ichi Yoshida, Satoshi Takenaka, Masayuki Ohue, Tomoyuki Yamasaki, Yasuhide Miyamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Miki Tanaka-OkamotoDepartment of Glyco-Oncology and Medical Biochemistry, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Ken HanzawaGlycoanalytical Chemistry Lab, Institute for Glyco-Core Research (iGCORE), Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan.
Takashi YamamotoDepartment of Clinical Laboratory, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Kazuyoshi OhkawaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Ken-Ichi YoshidaDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Satoshi TakenakaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Masayuki OhueDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Tomoyuki YamasakiDepartment of Clinical Laboratory, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Yasuhide MiyamotoDepartment of Clinical Laboratory, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan. yasuhide.miyamoto@oici.jp.

Funding

Grant-in-Aid for Scientific Research (C) 23K06880
6 · The paper itself

Abstract

Numerous urinary acidic free-glycan tumor marker candidates have been identified based on the glycan structure profiles of human cancer tissues. In this study, to identify novel glycan tumor markers, we performed precise glycan structural analysis focusing on neutral free-glycans in colorectal cancer tissues. Our analysis detected one free-glycan that was significantly elevated in colorectal cancer cells by comparison to the corresponding normal epithelial cells. Structural studies of this glycan revealed it to comprise a free-N-glycan with a difucosylated type-1 lactosamine structure (Lewis B antigen), rather than a conventional type-2 lactosamine structure. The presence of N-glycans with type-1 lactosamine structure has rarely been reported in humans. To investigate its clinical usefulness, the level of this free-glycan in the urine of 121 healthy subjects, 141 gastric cancer patients, 87 colorectal cancer patients, 55 pancreatic cancer patients, 13 bile duct cancer patients and 79 rare cancer patients were measured using a liquid chromatography-selected reaction monitoring assay. Significant differences were detected in cancer patient samples compared to healthy controls, with a marked increase in some rare-types of cancer patient samples, such as AFP-producing gastric cancer.

Indexed as

Amino SugarsBiomarkers, TumorColorectal NeoplasmsNeoplasmsPolysaccharidesAdultAgedFemaleHumansMaleMiddle AgedAmino SugarsBiomarkers, TumorlactosaminePolysaccharidesFree-glycanMass spectrometryTumor markerUrine

Identifiers

PMID41023053
PMCPMC12480888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.